Opendata, web and dolomites

AutArt

Clinical validation of the AutArt rheumatoid arthritis diagnostic device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AutArt project word cloud

Explore the words cloud of the AutArt project. It provides you a very rough idea of what is the project "AutArt" about.

image    drugs    mds    evaluation    lining    deformity    arthritis    line    eur    intensive    patients    282    selling    group    companies    sale    destroy    2020    agents    2014    precision    million    time    biologic    millions    monitoring    progression    first    software    sustainability    treatments    30    provides    competitors    inflammation    economic    became    considerably    automatically    successful    bone    people    serious    15    joints    causing    clinical    comparability    health    regular    causes    detection    disease    validation    2009    autart    heijde    disabled    action    sharp    ray    ineffective    social    treatment    medical    contributes    device    decreased    billion    objectivity    sold    precise    pharmaceutical    permanently    ra    cartilage    consists    estimate    follow    rheumatoid    regulation    union    van    sas    service    25    ten    modifying    rising    der    points    share    50    establishment    diagnosis    toolkit    feasibility    chronic    market    healthcare    autoimmune    act    diagnostic    dynamically    moment    diagnoses    scoring    scheduled   

Project "AutArt" data sheet

The following table provides information about the project.

Coordinator
BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: SZABOLCSKA MIHALY UTCA 1 FSZT 3
city: BUDAPEST
postcode: 1114
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Project website http://www.bifarma.hu
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIFARMA SZOFTVERFEJLESZTO ES TANACSADO KORLATOLT FELELOSSEGU TARSASAG HU (BUDAPEST) coordinator 50˙000.00

Map

 Project objective

The AutArt diagnostic toolkit is a medical device that automatically diagnoses the progression of Rheumatoid Arthritis (RA) on an X-Ray image by using the Sharp/van der Heijde scoring system. This Phase 1 feasibility study will support the clinical validation of the device in Phase 2 that we estimate will cost between 1.5-2 million EUR; with the first market sale scheduled within 2 years, sold SAS (Software as a Service). RA is a chronic autoimmune disease that causes inflammation of the lining of the joints, which can destroy cartilage and bone, causing deformity of the joints. RA is a serious economic and social problem, 20-30% of early RA patients become permanently work disabled during the first 2-3 years of the disease and more than 50% of patients with RA became work disabled during the first ten years of the disease. Classical disease-modifying drugs are ineffective in about 10-15% of the cases, furthermore, biologic agents may also be ineffective. Early detection, regular clinical monitoring and comparable, objective evaluation is essential for successful treatment. The AutArt medical device is the result of 2 years of intensive R&D and at the moment there are no serious competitors in the market, so this is the time to act for a dynamically rising market share in the RA diagnostic market. The target group consists of MDs, medical institutions and pharmaceutical companies. The unique selling points of the product are objectivity, comparability and precision. In the EU, RA treatments cost 25.1 billion EUR in 2009. With more precise diagnosis and objective follow-up this can be decreased considerably with the AutArt medical device. This project is in line with the 282/2014/EU regulation on the establishment of a third Programme for the Union’s action in the field of health (2014-2020) because it contributes to the sustainability of the healthcare system and provides millions of people with better treatment through more precise diagnosis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AUTART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AUTART" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More